Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052029 | 0.88 | ADRB1 (0.36) | ADRB1HTR2CHTR2B | |
| SCHEMBL31051789 | 0.86 | ADRB1 (0.40) | ADRB1KHKALDH1A1LMNACHEK1 | |
| SCHEMBL31052317 | 0.83 | ADRB1 (0.51) | ADRB1HTR2CHTR2B | |
| SCHEMBL31051933 | 0.82 | DRD2 (0.42) | ADRB1KHKALDH1A1LMNAKDM4E | |
| SCHEMBL31051949 | 0.82 | BCL2A1 (0.40) | ADRB1ALDH1A1LMNACHEK1HTR2C | |
| SCHEMBL31051963 | 0.82 | ADRB1 (0.39) | ADRB1KHKALDH1A1LMNACHEK1 | |
| SCHEMBL31052007 | 0.80 | ALDH1A1 (0.43) | ADRB1KHKALDH1A1LMNAHTR2C | |
| SCHEMBL31051758 | 0.77 | ADRB1 (0.36) | ADRB1HTR2CHTR2B | |
| SCHEMBL31052108 | 0.76 | DRD2 (0.42) | ALDH1A1HPGDHTR2C | |
| SCHEMBL31051755 | 0.75 | HTT (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |